Skip to main content
Transportation Update Actualización de transporte

SafeRide Health (SRH) is the new provider for all NEMT rides to doctor appointments and pharmacy visits.

Depending on your needs, rides may include wheelchair-lift-equipped vehicles, stretcher vans, minivans, or ambulatory vans. Please let SRH know what type of ride you need when scheduling.

Learn more

SafeRide Health (SRH) es el nuevo proveedor de todos los servicios de transporte médico que no son de emergencia (NEMT, por sus siglas en inglés) hacia consultas médicas y farmacias.

Según tus necesidades, los servicios de transporte pueden incluir vehículos con elevador para sillas de ruedas, camionetas con camilla, minivans o camionetas ambulatorias. Por favor, informa a SRH qué tipo de transporte necesitas al programar tu traslado.

Obtenga más información AQUI

Conduent Incident Incidente de Conduent

Revision to Makena Authorization Request Form 1345 Scheduled for June 10

Date: June 3, 2022 Attention: OB-GYN Providers Effective Date: June 10, 2022Providers should monitor the Texas Children’s Health Plan (TCHP) Provider Portal regularly for alerts and updates associated to the COVID-19 event.  TCHP reserves the right to update and/or change this information without prior notice due to the evolving nature of the COVID-19 event. Call to action:  On June 10, 2022, Health and Human Services Commission (HHSC) will revise the Makena (hydroxyprogesterone caproate injection) authorization request form because the brand name Makena 250 mg/ml is no longer eligible for Centers for Medicare and Medicaid Services rebates. How this impacts providers: HHSC removed the brand name Makena 250 mg/ml from the Texas Medicaid Formulary and the clinical prior authorization criteria guide. For patients requiring the 250mg dosing, the generic hydroxyprogesterone 250 mg/ml vial remains covered on Texas Medicaid Formulary with prior authorization criteria. Prior authorization criteria remains the same.  
Drugs Requiring Prior Authorization
HYDROXYPROGEST 1250 MG/5 ML
HYDROXYPROGEST 250 MG/ML VIAL
MAKENA 275 MG/1.1 ML AUTOINCT
  Next steps for providers: Prescribers should adjust their prescribing patterns accordingly and communicate these changes to their staff. Resource: https://paxpress.txpa.hidinc.com/makena.pdfIf you have any questions, please email Provider Network Management at: providerrelations@texaschildrens.org.For access to all provider alerts,log into: www.thecheckup.org or www.texaschildrenshealthplan.org/for-providers